ArticlePloS one2026
MUC5B rs35705950 and its association with survival in Brazilian patients with idiopathic pulmonary fibrosis: A longitudinal cohort study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with heterogeneous clinical outcomes. The MUC5B promoter polymorphism (rs35705950) is the most consistent genetic factor associated with IPF susceptibility, but data from Latin American populations remain limited.
methodsWe conducted a longitudinal cohort study including 50 patients with IPF and 45 healthy controls, recruited between August 1, 2018, and April 30, 2025, at a tertiary referral center in Brazil. Genotyping of rs35705950 was performed by real-time PCR. Demographic, clinical, and functional data were collected at baseline. Survival was analyzed using Kaplan-Meier curves and Cox regression models, with follow-up defined from symptom onset to death or censoring.
resultsThe T-allele frequency was higher in IPF patients compared with controls (47.1% vs 8.3%, p < 0.001). Carriers of the T allele (G/T or T/T) comprised 82.4% of cases versus 16.7% of controls. Among patients with IPF, T-carriers tended to have worse lung function and shorter survival, although survival differences were not statistically significant. In multivariable models, the presence of the T allele was not an independent predictor of mortality. By contrast, higher New York Heart Association (NYHA) functional class was consistently associated with increased mortality risk.
conclusionsIn this Brazilian cohort, the MUC5B promoter variant was strongly associated with susceptibility to IPF but not with independent survival differences. Functional impairment, particularly NYHA class, remained the key prognostic factor. These findings highlight the importance of integrating genetic and clinical information in diverse populations and provide novel data from an underrepresented Latin American setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.